Development of the protease-activated pro-antibody drug to enhance the specificity of disease target therapy
碩士 === 高雄醫學大學 === 生物醫學暨環境生物學研究所 === 100 === Therapeutic antibody drug is widely used to cure many diseases, and the global market have been climbed to 35.5 billion US dollars. However, the antibody treatment presented can’t distinguish the target antigen in disease region from normal region which ca...
Main Authors: | Yun-Chi Lu, 呂韻綺 |
---|---|
Other Authors: | Tian-Lu Cheng |
Format: | Others |
Language: | zh-TW |
Published: |
2012
|
Online Access: | http://ndltd.ncl.edu.tw/handle/hg23wr |
Similar Items
-
Real-time cancer imaging and therapy via protease specific pro-probe and pro-drug activation
by: Chih-HungChuang, et al.
Published: (2012) -
Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy
by: Wen-Wei Lin, et al.
Published: (2021-07-01) -
Specific activation of pro-Infliximab enhances selectivity and safety of rheumatoid arthritis therapy.
by: Yun-Chi Lu, et al.
Published: (2019-06-01) -
Towards a sequence-specific antibody protease
by: Smith, Robert Milton
Published: (1996) -
Enhanced activity of meprin-α, a pro-migratory and pro-angiogenic protease, in colorectal cancer.
by: Daniel Lottaz, et al.
Published: (2011-01-01)